Ashley Gallagher, Editor

Victor Ambros and Gary Ruvkun received the 2024 Nobel Prize in Physiology or Medicine for discovering microRNA and its role in gene regulation.

Investigators report the study met its primary end point, demonstrating that a single, oral dose reduced the transmission by those infected to others in their household.

Currently, Danon disease has a poor prognosis and does not have any pharmaceutical therapeutics for treatment or management.

In May 2024, the first biosimilars for aflibercept were approved, which included aflibercept-jbvf (Yesafili; Biocon Biologics), known as MYL-1701P.

The designation was based on results from the DESTINY-Breast06 trial, evaluating fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) compared with chemotherapy.

The findings support current recommendations for pregnant individuals or those who might become pregnant during the influenza season, specifically those with successive pregnancies.

Treatment for primary coenzyme Q10 (CoQ10) deficiency can include high-dose oral CoQ10 supplementation, but not all patients respond to this treatment.

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

Ustekinumab is a human monoclonal antibody targeting the cytokines interleukin (IL)-12 and IL-23, which play a rule in the inflammatory and immune responses.

Approximately 75% of adults trust their physicians, nurses, and pharmacists either a great deal or a lot, highlighting the importance of pharmacists for patient education.

MDL-101 is a proposed novel precision medicine that targets the LAMA1 gene, causing LAMA2 congenital muscular dystrophy type 1a.

Currently, the CDC recommends the recombinant zoster vaccine (Shingrix, RZV; GSK) for the prevention of herpes zoster and related complications.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

Investigators found a significant association for febrile seizures, but not with epilepsy.

The discontinuation comes after a review of the medication by the European Medicines Agency which found that “the total number of deaths was higher than anticipated.”

Treatment is typically tailored to the individuals, with HCT being the only curative treatment bone marrow failure, but long-term outcomes are generally poorer due to toxicities.

Additional education can address ambivalence for patients and providers, which can start at the pharmacist level, as they are essential sources of information for patients.

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

The FDA assigned a Prescription Drug User Fee Act action date of May 22, 2025.

In 2 studies, durvalumab improved overall survival for those with unresectable hepatocellular carcinoma and event-free survival for muscle-invasive bladder cancer.

Eosinophilic granulomatosis with polyangiitis is a rare and immune-mediate vasculitis that can damage multiple organs and be fatal if left untreated.

Eversense 365 (Senseonics) is the first long-lasting continuous glucose monitoring (CGM) system, which includes a 365-day sensor and only 1 insertion on Day 1 of every year.

The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).

Data show the value of the pharmacist is clear for patients with type 2 diabetes, as their role can have a significant impact on reductions in hemoglobin A1c.

Christian Rolfo discusses 6 different treatment options that are being developed across immunotherapies and antibody drug conjugates for non–small cell lung cancer and small cell lung cancer.

The Hearing Aid Feature can be customized to the user’s needs by amplifying sounds for individuals 18 years or older who have perceived mild to moderate hearing impairments.

Investigators obtained real-world evidence to evaluate the clinical outcomes of non-medical switching from the infliximab (Remicade; Janssen Immunology) to a biosimilar.

Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.

As of May 2024, follow-up and exploratory analyses of MARIPOSA show improvements in outcomes for patients with EGRF-mutated non–small cell lung cancer (NSCLC).

In a session at the 2024 World Conference on Lung Cancer, presenters highlight the most significant developments in local therapy for metastatic non–small cell lung cancer and advanced disease.